Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
27 Mars 2024 - 1:00PM
Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical
stage biopharmaceutical company focused on developing novel
therapeutics to address unmet medical needs in liver and viral
diseases, today announced three oral presentations and one poster
presentation at the 33rd Annual Meeting of the Asian Pacific
Association for the Study of the Liver (APASL) 2024, being held
March 27-31, 2024 in Kyoto, Japan.
The poster presentation highlights ALG-055009 Phase 1 data that
showed multiple-ascending doses (MAD) over 14 days in
hyperlipidemic subjects produced favorable, dose-dependent
pharmacodynamic effects on atherogenic lipids and sex hormone
binding globulin (SHBG), an indicator of target engagement in the
liver.
The three oral presentations provide interim data from Parts 3
and 4 of Aligos’ ALG-000184 Phase 1 extended dosing study showing
consistent, potent antiviral activity across different cohorts of
untreated CHB patients receiving once daily doses of ALG-000184 as
monotherapy or in combination with entecavir (ETV).
“We are pleased to present these additional Phase 1 data for
ALG-055009 and ALG-000184 at APASL 2024. After the recent
initiation of our Phase 2a HERALD study of ALG-055009 in MASH
subjects, we remain encouraged by the data presented showing a
favorable safety profile and strong evidence of target engagement,
as shown by induction of sex hormone binding globulin and lowering
of atherogenic lipids. We continue to believe our molecule has the
potential to be best-in-class,” said Lawrence Blatt, Ph.D., MBA,
Chairman, President, and Chief Executive Officer at Aligos
Therapeutics. “In addition, the three ALG-000184 oral presentations
demonstrate a consistent effect in the reduction of key viral
markers. These promising results affirm our belief that this
compound will play an essential role in the future treatment of
hepatitis B.”
Details of the presentations are as
follows:
ALG-055009: Potential best-in-class small molecule THR-β
agonist for metabolic dysfunction-associated steatohepatitis
(MASH)
- Poster Presentation Title: Pharmacodynamics of
Multiple Ascending Oral Doses of ALG-055009, a THR-β Agonist, in
Hyperlipidemic Subjects
- Presented by Megan Fitzgerald, Ph.D.
- March 28, 2024 at 5:10pm GMT+9
ALG-000184: Potential best-in-class small molecule CAM-E
for chronic hepatitis B (CHB)
- Oral Presentation Title: ALG-000184 (300mg) ±
Entecavir Results in Substantial HBV Antigen Declines in Untreated
HBeAg-Positive Subjects with CHB
- Presented by Professor Man-Fung Yuen, MBBS, MD, PhD, DSc, Chair
and Chief of the Division of Gastroenterology and Hepatology,
University of Hong Kong
- March 28, 2024 at 9:30am GMT+9
- Oral Presentation Title: ALG-000184 (100 mg) +
ETV Leads to Stronger Antiviral Effects Compared to ETV Alone in
HBeAg-Positive CHB
- Presented by Professor Jinlin Hou, MD, Director and Professor
of the Hepatology Unit and Department of Infectious Diseases,
Nanfang Hospital, Southern Medical University
- March 28, 2024 at 9:48am GMT+9
- Oral Presentation Title: ALG-000184 Has
Favorable Antiviral Effect & Safety in Untreated
Asian/Non-Asian HBeAg-Negative CHB Subjects
- Presented by Professor Man-Fung Yuen, MBBS, MD, PhD, DSc, Chair
and Chief of the Division of Gastroenterology and Hepatology,
University of Hong Kong
- March 28, 2024 at 9:57am GMT+9
The presentations can be found on the Scientific Presentations
& Conferences section of the Aligos website (www.aligos.com)
after the live event.
About AligosAligos Therapeutics, Inc. is a
clinical stage biopharmaceutical company that was founded in 2018
with the mission to become a world leader in the treatment of liver
and viral diseases. Aligos’ strategy is to harness the deep
expertise and decades of drug development experience its team has
in liver and viral diseases to discover and develop potentially
best-in-class therapeutics for metabolic dysfunction-associated
steatohepatitis (MASH) and viruses with high unmet medical need
such as chronic hepatitis B (CHB) and coronaviruses.
Forward-Looking Statement This press release
contains forward-looking statements within the meaning of the U.S.
Private Securities Litigation Reform Act of 1995. Any statements in
this press release that are not historical facts may be considered
“forward-looking statements,” including without limitation, with
respect to ALG-055009, statements that the company remains
encouraged by the data presented showing a favorable safety profile
and strong evidence of target engagement and continues to believe
the molecule has the potential to be best-in-class; and with
respect to ALG-000184, statements around the promising results
contained in the three oral presentations demonstrating consistent
effect in the reduction of key viral models, which results affirm
the company’s belief that this compound will play an essential role
in the future treatment of hepatitis B. Forward-looking statements
are typically, but not always, identified by the use of words such
as “may”, “will”, “would”, “believe”, “intend”, “plan”,
“anticipate”, “estimate”, “expect”, and other similar terminology
indicating future results. Such forward looking statements are
subject to substantial risks and uncertainties that could cause our
development programs, future results, performance, or achievements
to differ materially from those anticipated in the forward-looking
statements. Such risks and uncertainties include, without
limitation, risks and uncertainties inherent in the drug
development process, including Aligos’ clinical-stage of
development, the process of designing and conducting clinical
trials, the regulatory approval processes, the timing of regulatory
filings, the challenges associated with manufacturing drug
products, Aligos’ ability to successfully establish, protect and
defend its intellectual property, other matters that could affect
the sufficiency of Aligos’ capital resources to fund operations,
reliance on third parties for manufacturing and development
efforts, and the impact of global events and other macroeconomic
conditions on the Aligos business. For a further description of the
risks and uncertainties that could cause actual results to differ
from those anticipated in these forward-looking statements, as well
as risks relating to the business of Aligos in general, see Aligos’
Annual Report on Form 10-K filed with the Securities and Exchange
Commission on March 12, 2024 and its future periodic reports to be
filed or submitted with the Securities and Exchange Commission.
Except as required by law, Aligos undertakes no obligation to
update any forward-looking statements to reflect new information,
events or circumstances, or to reflect the occurrence of
unanticipated events.
Contacts
CompanyJordyn TaraziVice President, Investor
Relations & Corporate Communications(650)
910-0427jtarazi@Aligos.com
MediaMichael Fitzhugh LifeSci Communications
(628) 234-3889mfitzhugh@lifescicomms.com
Aligos Therapeutics (NASDAQ:ALGS)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Aligos Therapeutics (NASDAQ:ALGS)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024